These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1863837)

  • 1. Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue.
    Tsukamoto H; Nagasawa K
    Br J Rheumatol; 1991 Aug; 30(4):317. PubMed ID: 1863837
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral limaprost for Raynaud's phenomenon.
    Murai C; Sasaki T; Osaki H; Hatakeyama A; Shibata S; Yoshinaga K
    Lancet; 1989 Nov; 2(8673):1218. PubMed ID: 2572927
    [No Abstract]   [Full Text] [Related]  

  • 3. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon.
    DiGiovanni RL; Littlefield JM; Good RG
    J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment.
    Katoh K; Kawai T; Narita M; Uemura J; Tani K; Okubo T
    J Pharm Pharmacol; 1992 May; 44(5):442-4. PubMed ID: 1359062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raynaud's disease in childhood with radiological features.
    Shono T; Okadome K; Naritomi G; Suita S
    Br J Radiol; 1990 May; 63(749):364-6. PubMed ID: 2379063
    [No Abstract]   [Full Text] [Related]  

  • 10. Transdermal application of prostaglandin E1 ethyl ester for the treatment of trophic acral skin lesions in a patient with systemic scleroderma.
    Schlez A; Kittel M; Scheurle B; Diehm C; Jünger M
    J Eur Acad Dermatol Venereol; 2002 Sep; 16(5):526-8. PubMed ID: 12428854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The vasoprostan treatment of patients with Raynaud's syndrome].
    Alekperov RT; Mach ES; Guseva NG
    Ter Arkh; 1997; 69(8):22-3. PubMed ID: 9381386
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.
    Gaylarde PM
    Br Med J (Clin Res Ed); 1981 Dec; 283(6306):1608-9. PubMed ID: 6796187
    [No Abstract]   [Full Text] [Related]  

  • 13. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid effect of oral limaprost in Raynaud's disease in childhood.
    Shono T; Ikeda K
    Lancet; 1989 Apr; 1(8643):908. PubMed ID: 2564996
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 16. [Double-blind trial of oral prostaglandin E1 on impotence].
    Kawanishi Y; Kimura K; Iriguchi H; Miyamoto T; Tamura M; Numata A; Yuasa M; Kagawa S
    Nihon Hinyokika Gakkai Zasshi; 1992 Oct; 83(10):1655-61. PubMed ID: 1434268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.
    Lucas GS; Simms MH; Caldwell NM; Alexander SJ; Stuart J
    J Clin Pathol; 1984 Aug; 37(8):870-3. PubMed ID: 6540787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of Raynaud's phenomenon.
    Dowd PM
    Br J Dermatol; 1986 May; 114(5):527-33. PubMed ID: 2872912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.